Health Farm invests significantly in the alignment of various medical technologies that, although researched, developed and marketed in the industrialised world, can also be used extensively to benefit the developing world.  One such strategic partnership is with DG Medical Technologies in the research & development and commercialisation of a novel nanotechnology that has proven to be transformative at treating chronic wounds, dramatically improving patients’ quality of life, and reducing the need for surgical rooms/resources, and expensive hospital requirements. 

This technology has been used when standard of care has failed for a wide variety of chronic wounds such as diabetic foot ulcers and pressure ulcers. Beyond facilitating natural wound healing, this technology has demonstrated broad-spectrum antimicrobial effectiveness against a myriad of common and resistant strains of bacteria, fungi, and viruses. It is highly effective at eliminating pathogens, while yielding extremely low cytotoxicity results on healthy cells; essentially showing strong specificity towards the microorganisms it aims to eliminate. 

The costs associated with chronic wounds extend beyond the health system and have a significant impact on economies; chronic wounds precede 85% of all amputations and significantly contribute to premature deaths. This burden is increasing with the ageing population and life-style diseases including diabetes and obesity.